FDA approves Ono’s rare joint tumor drug, setting up battle with Daiichi
The FDA approval of Romvimza in a rare cancer means Ono Pharmaceutical has a fight on its hands. The company must work to displace Daiichi …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
